As a result of the knockdown of NFATC3-PLA2G15, invasion and proliferation are inhibited in cancer cells, suggesting that NFATC3-PLA2G15 FTs may influence CRC progression; these impact findings show that this fusion transcript can serve as a novel biomarker for CRC [82] TGFRN-NOTCH2 fusion transcripts were the only transcripts detected in CRC and adjacent normal tissues from deep transcriptome sequencing. The gene discussed is NFATC3; the disease is cancer.